Skip to content
AnalystLens

Cigna Group 8-K Report, Corporate Update (Feb 7, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed February 7, 2024
Period End
February 5, 2024
Security
CI
In the record · 2018–202610-K810-Q238-K136

CI filed 8 annual reports (10-K), 23 quarterly reports (10-Q) and 136 current reports (8-K) between 2018 and 2026.

  1. Deal closed8-K · Feb ’19Feb ’19
  2. Material agreement8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’23May ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 7, 2024. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group (CI) has announced a significant debt issuance, filing an 8-K report on February 7, 2024, detailing the sale of $4.5 billiona in aggregate principal amount of Senior Notes across various maturities.

These notes include 5.000% Senior Notes due 2029 ($1 billionb), 5.125% Senior Notes due 2031 ($750 million), 5.250% Senior Notes due 2034 ($1.25 billion), and 5.600% Senior Notes due 2054 ($1.5 billion). This debt issuance is strategically aimed at financing its previously announced tender offers for outstanding notes with maturities between 2024 and 2030, up to an aggregate principal amount of $2.25 billion.

Any remaining proceeds will be allocated towards the repayment of its 0.613%c Senior Notes due 2024 at maturity and for general corporate purposes, which could include further debt repayment or share repurchases. This move indicates a proactive approach to managing its debt profile and capital structure.

02—Key points

Key Highlights

  1. Cigna Group issued $4.5 billion in Senior Notes across four tranches with varying interest rates and maturity dates (2029, 2031, 2034, 2054).
  2. The issuance includes notes with coupon rates ranging from 5.000% to 5.600%.
  3. Proceeds are earmarked to fund tender offers for up to $2.25 billion of existing outstanding notes.
  4. Remaining funds will be used to repay 0.613% Senior Notes due 2024 at maturity.
  5. General corporate purposes, including potential debt repayment and share repurchases, are also covered by the remaining proceeds.
  6. The debt issuance was conducted under the company's existing shelf registration statement on Form S-3ASR.
  7. The Underwriting Agreement includes standard provisions for representations, warranties, conditions, indemnification, and termination.

03—Questions

Frequently Asked Questions

  1. What is the primary purpose of this $4.5 billion debt issuance?

    The primary purpose is to refinance existing debt. The company intends to use the proceeds to fund its announced tender offers for outstanding notes and to repay maturing debt obligations, with any remainder for general corporate purposes.

  2. What are the specific terms of the new Senior Notes being issued?

    Cigna Group is issuing $1 billion of 5.000% Senior Notes due 2029, $750 million of 5.125% Senior Notes due 2031, $1.25 billion of 5.250% Senior Notes due 2034, and $1.5 billion of 5.600% Senior Notes due 2054.

  3. How does this debt issuance affect Cigna Group's overall debt structure?

    This issuance allows Cigna Group to proactively manage its debt maturity profile by retiring near-term debt with longer-term debt. It also provides flexibility for future capital allocation decisions, such as share repurchases or further debt reduction.

  4. What is the significance of the 'tender offers' mentioned in the filing?

    The tender offers are an invitation to existing bondholders to sell back their notes to Cigna Group, typically at a premium, before their scheduled maturity. This issuance provides the capital necessary to complete those buybacks, indicating a strategy to optimize the company's outstanding debt.

04—Continue

← View all 8-K filings